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6-Thioguanine blocks SARS-CoV-2
replication by inhibition of PLpro
Caleb D. Swaim,1 Varun Dwivedi,2 Yi-Chieh Perng,3 Xu Zhao,1 Larissa A. Canadeo,1 Houda H. Harastani,3
Tamarand L. Darling,3 Adrianus C.M. Boon,3,4,5 Deborah J. Lenschow,3,4 Viraj Kulkarni,2
and Jon M. Huibregtse1,6,*
SUMMARY

The emergence of SARS-CoV-2 has led to a global health crisis that, in addition to vaccines and immunomodulatory therapies, calls for the identification of antiviral therapeutics. The papain-like protease (PLpro) activity of nsp3 is an attractive drug
target as it is essential for viral polyprotein cleavage and for deconjugation of
ISG15, an antiviral ubiquitin-like protein. We show here that 6-Thioguanine (6-TG),
an orally available and widely available generic drug, inhibits SARS-CoV-2 replication
in Vero-E6 cells with an EC50 of approximately 2 mM. 6-TG also inhibited PLpro-catalyzed polyprotein cleavage and de-ISGylation in cells and inhibited proteolytic
activity of the purified PLpro domain in vitro. We therefore propose that 6-TG is a
direct-acting antiviral that could potentially be repurposed and incorporated into
the set of treatment and prevention options for COVID-19.
INTRODUCTION
Coronavirus Disease-2019 (COVID-19) is caused by SARS-CoV-2, a betacoronavirus highly similar to SARSCoV-1 (now SARS-CoV-1) (Coronaviridae Study Group of the International Committee on Taxonomy of Viruses, 2020; Gralinski and Menachery, 2020). An urgent need exists for additional treatment strategies, and
repurposed FDA-approved drugs with existing supply chains and well characterized pharmacologic properties represent a rapid and efficient approach toward COVID-19 therapeutics (Guy et al., 2020).
Enzymatic activities encoded by SARS-CoV-2 are attractive drug targets, including PLpro, an essential
cysteine protease within the large multi-domain nsp3 protein (Harcourt et al., 2004). PLpro cleaves the
pp1a polyprotein at three sites and is required to generate the mature nsp1, 2, 3 and 4 proteins. These proteins modulate host cell translation (nsp1) and contribute to formation of viral replication/transcription
complexes (nsp2, 3, and 4) (V’kovski et al., 2021). The PLpro recognition consensus site within pp1a
(LXGG) is also found at the C-terminus of ubiquitin and ISG15, an antiviral ubiquitin-like modifier, although
PLpro of MERS-CoV, SARS-CoV-1, and SARS-CoV-2 PLpro preferentially catalyzes de-ISGylation over ubiquitylation (Daczkowski et al., 2017; Freitas et al., 2020). The fact that these viruses encode de-ISGylase activity suggests they are sensitive to the antiviral effects of ISGylation. Therapeutic inhibition of PLpro would
therefore be predicted to have two antiviral effects: inhibition of viral replication by blocking polyprotein
cleavage and restoration of the antiviral effects of ISGylation. Further, de-ISGylation by PLpro, through
generation of free (unconjugated) ISG15, enhances the secretion and extracellular signaling function of
ISG15, which in turn promotes pro-inflammatory cytokine production from cells of the immune system
(Swaim et al., 2020). Therefore, a potential third effect of inhibiting PLpro would be a decrease in the
pro-inflammatory ‘‘cytokine storm’’ associated with COVID-19 (Tay et al., 2020). Here, we show that an
inhibitor of SARS-CoV-2 PLpro, 6-thioguanine (6-TG), inhibits virus replication at low micromolar concentrations. 6-TG is a widely available generic drug that could therefore potentially be repurposed as a betacoronavirus therapeutic in the current and future pandemics.

RESULTS
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6-Thioguanine inhibits SARS-CoV-2 replication
6-Thioguanine (Figure 1A) has been used clinically since the 1950s, originally for the treatment of childhood
leukemias and subsequently for long-term treatment of inflammatory bowel disease (IBD) and Crohn’s disease (Bayoumy et al., 2020). 6-TG was previously reported to inhibit the SARS-CoV-1 and MERS-CoV PLpro
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Figure 1. 6-TG inhibits SARS-CoV-2 viral replication in Vero-E6 cells
(A) The structure of 6-Thioguanine (6-TG).
(B) Vero-E6 cells were treated with 6-TG, Remdesivir, GRL0617, and Azathioprine to assess their ability to restrict SARSCoV-2 replication (MOI: 0.01). Drug concentrations for 6-TG, GRL0617 and Azathioprine ranged from 0.1 pM to 100 mM at
10-fold increments; concentrations for Remdesivir ranged from 5 nM to 100 mM at 3-fold increments. Percent inhibition of
viral replication was calculated by comparing plaques in drug-treated samples to those in DMSO treated samples and
shown as mean G SED for either four replicates (6-TG, GRL0617 and Azathioprine) or two replicates (Remdesivir). The
calculated EC50 for the compounds are shown in each panel with 95% confidence limits.

catalytic domain in vitro (Cheng et al., 2015; Chou et al., 2008); however, there was no further follow up of its
ability to inhibit de-ISGylation or viral polyprotein cleavage in cells or its ability to inhibit viral replication.
6-TG was therefore tested for its ability to inhibit SARS-CoV-2 replication in Vero-E6 African Green Monkey
kidney cells. As shown in Figure 1B, 6-TG inhibited viral replication with a half-maximal effective concentration (EC50) of 2.13 mM. Remdesivir, a SARS-CoV-2 therapeutic and an inhibitor of the viral RNA-dependent RNA polymerase (Yin et al., 2020), inhibited replication with a very similar EC50, 2.16 mM. GRL0617, a
previously reported inhibitor of SARS-CoV-2 PLpro inhibited replication with an EC50 approximately
15-fold higher than 6-TG (35.43 mM), consistent with previously reported results (Freitas et al., 2020). Azathioprine, a thiopurine related to 6-TG that is also used clinically for IBD (Bayoumy et al., 2020), was approximately 10-fold less effective at inhibiting viral replication than 6-TG (EC50 19.16 mM). The cytotoxicity of
these compounds was determined, and the CC50 (50% cytotoxic concentration) ranged from approximately 35 mM for 6-TG to 60 mM for Remdesivir (Figure S1).

6-Thioguanine inhibits PLpro activity in cells and in vitro
An essential role of the PLpro domain of nsp3 is to generate the mature nsp1-4 proteins from the pp1a polyprotein through self-catalyzed cleavage reactions. To determine if 6-TG inhibited polyprotein cleavage
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Figure 2. 6-TG inhibits viral polyprotein cleavage
(A) (Top) Schematic representation of the TAP-nsp123 fusion protein. Arrows indicate sites of PLpro-catalyzed cleavage.
(Bottom) HEK293T cells were transfected with plasmids expressing either TAP-nsp1, TAP-nsp123WT or TAP-nsp123CA.
6-TG was added at the time of plasmid transfection and at the indicated final concentrations. Total cell lysates were
prepared 48 h post-transfection and analyzed by immunoblotting with anti-TAP antibody. Bands corresponding to TAPnsp1 and the full-length fusion proteins are indicated. Bracketed bands (*) represent breakdown products of the fulllength WT or CA fusion proteins.
(B) (Top) Schematic representation of the TAP-nsp2-3 fusion protein. Arrow indicates site of PLpro-catalyzed cleavage.
(Bottom) HEK293T cells were transfected with plasmids expressing TAP-nps2-3, and TAP-PLpro (WT or CA) and treated
with 6-TG at the indicated final concentrations for 48 h. Total cell cell lysates were analyzed by TAP immunoblot. Bands
corresponding to TAP-PLpro, TAP-nsp2-3 and TAP-nsp2 are indicated.

events in HEK293T cells, we expressed by plasmid transfection an N-terminally TAP-tagged pp1a protein
consisting of the full-length nsp1, 2 and 3 proteins (TAP-nsp123WT; Figure 2A). We also expressed a version
of the protein with the active-site cysteine within the PLpro domain of nsp3 altered to an alanine (TAPnsp123C A). The fusion proteins were detected by immunoblotting of cell lysates with anti-TAP antibody,
and TAP-nsp1 was expressed separately as a size marker for the processed fusion protein. Expression of
TAP-nsp123WT resulted primarily in a product the size of TAP-nsp1 (42 kD), as expected if the fusion protein
was fully processed, whereas expression of TAP-nsp123C A resulted in the expected full-length protein
(336 kD) along with several breakdown products of the full-length protein. Increasing concentrations of
6-TG inhibited PLpro-mediated processing of the TAP-nsp123WT polyprotein, with loss of the TAP-nsp1
product and accumulation of the full-length fusion protein, with the same pattern of breakdown products
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Figure 3. 6-TG inhibits PLpro-mediated de-ISGylation in cells and in vitro
(A) HEK293T cells were transfected with plasmids expressing FLAG-ISG15 and the ISG15 E1/E2/E3 enzymes and 0.2 mg of
PLpro plasmid (WT or CA) where indicated. 6-TG was added at the time of transfection and at the indicated final
concentrations. Total cell lysates were prepared 48 h post-transfection and analyzed by immunoblotting to detect FLAGISG15 and FLAG-ISG15 conjugates.
(B) (Top) Schematic of Pro-ISG15-HA where the mature ISG15 protein sequence (green) is expressed with its natural
C-terminal extension (yellow), followed by an HA epitope tag. (Bottom) Purified Pro-ISG15-HA protein (100 ng) was
incubated with the indicated concentrations of PLpro and 6-TG for 30 min and analyzed by HA immunoblot.

seen with the TAP-nsp123C A protein (Figure 2A). Half-maximal inhibition of polyprotein cleavage
occurred at approximately 0.5 mM 6-TG (quantitation shown in Figure S2A). In a related experiment (Figure 2B), the isolated PLpro domain (residues 746-1061 of nsp3) was co-expressed in trans with a TAPtagged nsp2-nsp3 fragment (residues 727-918 of pp1a), spanning the nsp2-3 PLpro cleavage site. PLpro
efficiently processed the TAP-nsp2-3 protein, dependent on the active-site cysteine, and this was again inhibited with increasing amounts of 6-TG, with half-maximal inhibition at approximately 1.0 mM 6-TG (quantitation shown in Figure S2B).
In addition to polyprotein cleavage activity, SARS-CoV-2 PLpro deconjugates ISG15 from proteins that
have been modified by this antiviral ubiquitin-like protein (Klemm et al., 2020; Shin et al., 2020; Swaim
et al., 2020). The E1, E2, and E3 enzymes for conjugation of human ISG15 are Uba7, Ube2L6, and Herc5,
respectively, and expression of these enzymes with ISG15 results in robust protein ISGylation in cells (Dastur et al., 2006). Figure 3A shows that co-expression of PLpro (residues 746-1061 of nsp3) with ISG15 and the
ISG15 conjugation enzymes in HEK293T cells resulted in nearly complete loss of ISG15 conjugates, whereas
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expression of the active-site C-to-A variant of PLpro (PLproC A) did not. Addition of 6-TG resulted in a
dose-dependent inhibition of PLpro de-ISGylation activity, with half-maximal inhibition at approximately
0.1 mM (quantitation shown in Figure S2C). To demonstrate that 6-TG acts directly on PLpro, an in vitro
cleavage assay was established based on an ISG15 fusion protein. Like most ubiquitin-like proteins,
ISG15 is synthesized in cells as a precursor protein with a C-terminal extension that must be proteolytically
removed prior to conjugation. We expressed and purified the precursor form of ISG15 with an additional
C-terminal HA tag (Pro-ISG15-HA), and this was used as a substrate for the purified PLpro domain (nsp3
residues 746-1061). As shown in Figure 3B, purified PLpro proteolytically removed the HA-tagged C-terminal extension, and increasing amounts of 6-TG inhibited the reaction, dependent on the input amount of
PLpro enzyme (quantitation shown in Figure S2D). These results indicate that 6-TG directly inhibits SARSCoV-2 PLpro.

DISCUSSION
The results shown here indicate that 6-TG is a direct-acting SARS-CoV-2 antiviral that functions by inhibiting
the PLpro activity of the nsp3 protein. 6-TG inhibited both pp1a polyprotein processing in cells and the
ISG15 deconjugation activity of PLpro in cells and in vitro. Pp1a polyprotein cleavage is essential for
generation of the nsp1-4 viral proteins, and therefore essential for virus replication. Inhibition of ISG15
conjugation is likely to have a less important effect in cell-based replication assays but may have important
consequences during an infection in an animal or human host. The fact that MERS-CoV and SARS-CoV-1
PLpro also have de-ISGylase activity suggests these viruses are particularly sensitive to the antiviral effects
of ISG15. Although the critical targets of ISG15 conjugation in infected cells are not yet known, we speculate that these may include newly translated viral proteins, as suggested earlier (Durfee et al., 2010), and
perhaps the pp1a protein, itself.
6-TG is an orally-delivered generic drug on the World Health Organization list of essential medicines, suggesting that it could be potentially re-purposed as an inexpensive and widely available therapeutic for
COVID-19. Clinical trials are essential for determining the effectiveness of 6-TG against COVID-19. Four
clinically approved hepatitis C protease inhibitors (Semeprevir, Paritaprevir, Vaniprevir, and Grazoprevir)
have also recently been shown to inhibit SARS-CoV-2 PLpro in vitro and virus replication in Vero-E6 cells
(Bafna et al., 2021). The EC50s for inhibition of viral replication for these drugs ranged from 4.25 to
10.8 mM, while that of 6-TG was determined here to be 2.13 mM. Although 6-TG directly inhibited PLpro
activity, it should be noted that the mechanism of action of 6-TG as a chemotherapeutic and immunosuppressant is that it is converted into 6-Thioguanine ribonucleotides and deoxynucleotides and incorporated
into RNA and DNA. It is therefore possible that incorporation of 6-TG-containing ribonucleotides into
SARS-CoV-2 RNA could be a secondary antiviral effect of 6-TG.
Current 6-TG dosing in patients varies significantly, from 0.3 mg/kg/day for long-term treatment of inflammatory diseases, to up to 3 mg/kg/day in acute lymphocytic and myelogenous leukemia treatments (Seinen
et al., 2010). Hepatotoxicity and bone marrow suppression are significant side effects of high dose treatment (2-3 mg/kg/day); however, this is typically not seen before two courses of treatment (2 months).
6-TG as an IBD therapeutic involves continuous doses of 0.3 mg/kg/day for more than a year, a dosage
that results in fewer cases of liver and myeloid toxicities (Meijer et al., 2016; Mulder et al., 2014). Although
it may seem counterintuitive to use a immunosuppressive as an antiviral, evidence to date indicates that
IBD patients on thiopurine therapies do not have higher rates of COVID-19 than the general population
(Higgins et al., 2020). Further, as a potential COVID-19 treatment, we anticipate that 6-TG treatment
courses would be on the order of 5–10 days, like Remdesivir, and therefore toxicities and immune-suppression associated with prolonged or high dose 6-TG treatment are unlikely to be relevant. Also like Remdesivir, we anticipate that 6-TG would be most effective if administered early in the course of a SARS-CoV-2
infection, during the peak viral replication phase. We note that unlike 6-TG, Remdesivir must be delivered
intravenously. We propose that the results presented here warrant the initiation of human clinical trials of
6-TG as a SARS-CoV-2 therapeutic. As PLpro is a conserved and essential enzymatic activity of the beta coronaviruses, 6-TG may prove useful in the current and future coronavirus pandemics and as a complement
to other antivirals in use and in development.

Limitations of study
SARS-CoV-2 plaque assays were performed only in African Green Monkey Vero-E6 cells, and it is possible
that replication assays in human cells, such as Calu3 or normal human airway epithelial cells would have
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given different IC50 values that would be more relevant in considering possible human clinical trials. An
additional limitation of the study is that the effects of 6-TG were not tested in a whole animal model of
SARS-CoV-2 infection. Human clinical trials will ultimately be necessary to determine the effectiveness of
6-TG as a COVID-19 therapeutic.
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RRID: AB_2533325

Anti-Actin

Thermo Scientific

RRID: AB_2536382

Antibodies

Bacterial and virus strains
BL21 GST-SARS-CoV-2 PLpro

This paper

BL21 GST Pro-ISG15-HA

This paper

2019 n-CoV/USA_WA1/2020

CDC

CDC/BEI Resources NR52281

PreScission Protease

GE Healthcare

CAT#27-0843-01

CellTiter-Glo 2

Promega

CAT#G9241

6-Thiogunaine

TCI

CAT#T0212

GLR0617

MCE

CAT#HY-117043

Remdesivir

APEXBIO

CAT#B8398

Azathioprine

TCI

CAT#A2069

Isopropyl b-D-1-thiogalactopyranoside

FisherSci

CAT#BP1755-10

Vectastain ABC HRP

Vector Labs

CAT#PK-4000

X-treamGENE HP DNA transfection reagent

Sigma

CAT#6366546001

Vero E6 cells

ATCC

CAT#CRL-1586

HEK293T cells

ATCC

CAT#CRL-3216

Chemicals, peptides, and recombinant proteins

Experimental models: Cell lines

Recombinant DNA
pcDNA3 UBE1L

(Durfee et al., 2008)

pcDNA3 UBCH8

(Durfee et al., 2008)

pcDNA3 HA HERC5

(Durfee et al., 2008)

pcDNA3 3xFLAG-WT ISG15
pGEX-6p SARS-CoV-2 PL

pro

pcDNA TAP-NSP123WT

(Swaim et al., 2017)
This paper
This paper

pcDNA TAP-NSP123 C1675A

This paper

pcDNA NTAP SARS-CoV-2 PLpro

Swaim et al., 2020

pcDNA NTAP SARS-CoV-2 PLpro C110A

Swaim et al., 2020

Software and algorithms
Prism 8

Graphpad

Other
BOLT Bis Tris 4-12% gel

Thermo Scientific

Sera mag speed bead protein AG

GE lifesciences

CAT#NW04120BOX

NuPAGE Tris Acetate 3-8% gel

Thermo Scientific

CAT#EA0375PK2

Protein A sepharose

Invitrogen

CAT#101141

Glutathione Sepharose

GE Healthcare

CAT#17075601
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RESOURCE AVAILABILITY
Lead contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by
the lead contact, Jon Huibregtse (huibregtse@austin.utexas.edu).

Material availability
All newly generated reagents for this study are available at the institution of the lead contact.

Data and code availability
Not applicable.

EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cells, viruses, and compounds
All cell lines were maintained at 37 C, 5% v/v CO2 in a humidified incubator. HEK293T cells were grown in
DMEM (Corning) supplemented with 10% FBS (Sigma) and 1% Penicillin-Streptomycin (Corning). Vero-E6
(ATCC), were cultured at 37 C, 5% v/v CO2 in a humidified incubator in Dulbecco’s Modified Eagle medium
(Corning) supplemented with 10% FBS (HyClone), 1% Penicillin-Streptomycin (Corning), 10 mM HEPES
(Corning), and 1X non-essential amino acids (Sigma). Infections and culture post infection was conducted
in DMEM with 2% FBS, 1% Penicillin-Streptomycin, 10mM HEPES, and 1X non-essential amino acids.
SARS-CoV-2, USA-WA1/2020 strain (Genbank: MN985325.1), was obtained from The Biological and
Emerging Infections Resources Program (BEI Resources NR-52281). A 6th passage (P6) of SARS-CoV-2
was generated by infecting Vero-E6 cells obtained from ATCC (CRL-1586) for 72 hours (h). At 72 h post
infection, culture supernatants were collected, clarified, and aliquots were stored at -80 C. Viral titers
were calculated by conventional plaque assay.

Plasmids
pcDNA3.1-TAP-PLproWT and pcDNA3.1-TAP-PLproCA were described in Swaim et al. (2020). pcDNA3.1TAP-nsp123 was generated from a partial orf1ab clone (S2-A2_p57 plasmids) encoding residues 1-1504;
nsp1, nsp2, and part of nsp3; (gift from Hongbing Jiang and David Wang, Washington University School
of Medicine ) with the remainder of the nsp3 ORF (residues 1505 - 2767 of pp1a, derived from Addgene
cat# 141257). The pcDNA3.1-TAP-nsp123 active site variant (C to A substitution, residue 1675 of polyprotein 1a, corresponding to residue 856 of mature nsp3) was generated from this clone by overlapping PCR.
Plasmids expressing FLAG-ISG15, and the ISG15 E1, E2, and E3 enzymes (Uba7, Ube2L6, and Herc5) have
been described previously (Swaim et al., 2017). Pro-ISG15-HA was generated by appending the natural
C-terminal ISG15 extension and an HA-tag (GTEPGGRSYPYDVPDYA) to the C-terminus of FLAG-ISG15.
The TAP-nsp2-3 was generated by amplifying the region encoding the last 92 amino acids of nsp2 and
the first 100 amino acids of nsp3 (residues 727-918 of pp1a) from TAP-nsp123 and cloning it into
pcDNA-NTAP using the BamH1 and Not1 restriction sites.

METHOD DETAILS
Transfections and drug treatments
HEK293T cells were plated in a 6 well plate at a density of 3x104 cells/mL. The next day cells were transfected using X-tremeGENE HP DNA transfection reagent (Roche). Plasmids were transfected at the
following amounts: 0.35 mg FLAG-ISG15, 0.25 mg Uba7, 0.25 mg Ube2L6, 0.35 mg HA-Herc5, 1 mg TAPnsp123 (WT or CA), 0.2 mg TAP-PLpro (WT or CA) Cells were treated with 6-TG at the indicated concentrations immediately following transfection (100 mM 6-TG stock in DMSO and diluted in PBS).

Protein purification
Sars-CoV-2 PLpro was purified as a GST fusion protein in BL12 E. coli. Overnight starter cultures were grown
at 37 C for 16 hours. Cultures were diluted 1:10 and cultured with shaking for 2 hours at 37 C. Expression of
protein was induced with 100 mM Isopropyl b-D-1-thiogalactopyranoside (IPTG) for 24 hours at 16 C. Cells
were collected by centrifugation, resuspended in 10 mL TBS with 0.00025% Tween 20, 0.01 mM DTT and 5%
glycerol (Binding Buffer), and sonicated for 1 minute. Lysates were spun at 15,000 x g for 10 minutes and
supernatants were incubated with 100 mL per liter of culture Glutathione Sepharose (GE Healthcare) for
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4 hours with rotation at 4 C. Beads were collected and washed three times with Binding Buffer supplemented with 0.1mM EDTA and subjected to site-specific cleavage with PreScission Protease (GE Healthcare) to remove the GST tag. Beads were removed and the protein concentration in the supernatant
was quantified by SDS-PAGE using a Licor Odyssey Imager.
Pro-ISG15-HA was purified as a GST fusion from BL21 E. coli. Overnight starter cultures were grown at 37 C.
Cultures were diluted 1:10 with shaking for 2 hrs at 37 C. Expression of protein was induced with 100 mM
Isopropyl b-D-1-thiogalactopyranoside (IPTG) for 3 hours at 30 C. Cells were collected by centrifugation
and resuspended in PBS with 1% Triton X and sonicated for 30 seconds. Lysates were spun at 15,000 x g
for 10 minutes and supernatants were incubated with 100 mL per liter of culture Glutathione Sepharose
(GE Healthcare) for 4 hours with rotation at 4 C. Beads were collected and washed three times with Binding
Buffer supplemented with 0.1mM EDTA and subjected to site-specific cleavage with PreScission Protease
(GE Healthcare) to remove the GST tag. Beads were removed and the protein concentration in the supernatant was quantified by SDS-PAGE using a Licor Odyssey Imager.

Pro-ISG15-HA cleavage assay
The indicated concentrations of PLpro were incubated with increasing concentrations of 6-TG for 1 min at a
40 mL volume. 100 ng (166 nM) of Pro-ISG15-HA was added to the PLpro-6-TG reactions for 30 min. The
reactions were stopped with the addition of 10mL of loading buffer (25mM Tris pH6.8 40% glycerol, 8%
SDS and 4mM DTT) and analyzed by HA-immunoblot; loss of the HA tag reflects proteolytic cleavage by
PLpro.

Immunoblotting and immunoprecipitations
Samples assessing ISGylation were lysed in 1% NP40 lysis buffer (100 mM Tris pH 7.5, 100 mM NaCl ,1%
NP40) supplemented with 10 mM NEM, 170 mg/mL PMSF, 2 mg/mL leupeptin, 2 mg/mL aprotinin and
10 mM DTT for 10 minutes on ice followed by a 10 minute spin at 20,000 x g. Samples were run on BOLT
4-12% Bis-Tris gels (Thermo) and blotted with anti-M2 FLAG antibody (Sigma) and anti-actin (Invitrogen
AC-15). Samples assessing the effect of 6-TG on TAP-nsp123 cleavage were lysed in RIPA buffer (50 mM
Tris pH 8, 150 mM NaCl, 0.5% NP40, 0.1% SDS, 0.5% Sodium deoxycholate w/v) supplemented with
10 mM NEM, 170 mg/mL PMSF, 2 mg/mL leupeptin, 2 mg/mL aprotinin, 10 mM DTT, and 2 units/mL Universal
Nuclease (Pierce) and incubated for 10 minutes on ice followed by a 10 minute spin at 20,000 x g. Samples
were run on 3-8% Tris-Acetate gels (Thermo) and blotted for TAP using anti-protein A antibody (Sigma) and
anti-actin (Invitrogen AC-15).

Virus replication and plaque assays
Vero-E6 cells (2 x 104 cells/well) were seeded in 96-well culture plates in DMEM +10% FBS+P/S/G and incubated at 37 C, 5% CO2. After 24 h, Vero-E6 cells were infected with SARS-CoV-2 (MOI 0.01; 50 ml) for 1 h at
37 C; 5% CO2. After 1 h of viral adsorption, virus inoculum was removed and post-infection media
(DMEM + 2% FBS + P/S/G) containing ten-fold serially diluted 6-TG, GLR0617, and Azathioprine
(100 mM to 0.1 pM) with 1% Avicel was added. Remdesivir was diluted 3-fold (100 mM-0.01 mM) and served
as a positive control. Cells infected with SARS-CoV-2 only, cells alone (mock infected cells), and DMSO,
were included as controls. At 24 h post-infection, the overlay media was removed and plates were fixed
overnight in 10% neutral buffered formalin (Sigma-Aldrich), followed by 3 washes with PBS. Cells were
stained with SARS-CoV nucleocapsid (N) protein cross-reactive monoclonal antibody (mAb, 1C7C7, Cat#
ZMS1075, Sigma-Aldrich, Saint Louis, MO) diluted in 1% Bovine Serum Albumin (BSA,1 mg/ml) for 1 h at
37 C and washed with PBS. 150 mL of biotinylated secondary antibody was added (Vector Laboratories
PK-4000) for 30 min at 37 C with 5% CO2. Post secondary antibody incubation the ABC reagent was added
for 30 min at room temperature (Vector Laboratories PK-4000). Plates were washed 3 times with PBS and
developed using DAB staining (Vector Laboratories SK-4100) per manufacturer’s instructions. The plates
were scanned using a CTL ImmunoSpot plate reader, and formed plaques were counted by an automated
counting software (Cellular Technology Limited, Cleveland, OH, USA). Plaque forming units were calculated relative to DMSO treated controls.

Cytotoxicity assays
CellTiter-Glo 2.0 (Promega) was used to determine the cytotoxicity of Remdesivir, 6-TG, GLR0617, and
Azathioprine. Vero-E6 cells were seeded in a 96 well white clear bottom plate at 2.5x105 cells per well in

10

iScience 24, 103213, October 22, 2021

iScience
Article

iScience

ll

Article

OPEN ACCESS

100 mL of media for 16 hours. Compounds including a DMSO control were added at the indicated concentrations for 48 hours in triplicate. After 48 hours the plate was brought to room temperature and 100mL of
CellTiter-Glo 2.0 was added to each well. The plate was placed on an orbital shaker for 2 minutes and then
incubated in the dark for 10 minutes. The plate was read on a spectromax M3 plate reader luminometer
with an integration time of .5 seconds per well. Luminescence of compound treated samples was compared
to no-cell background and to DMSO treated cells to determine percent survival, and plotted using Graphpad Prism 9. Non linear fit vs. normalized response with variable slope was used to calculate CC50 values for
each compound.

QUANTIFICATION AND STATISTICAL ANALYSIS
Graphpad Prism 9 software was used to plot virus replication and densitometry data. Bars represent three
or more biological replicates. Error bars represent the standard error of the mean (SEM). Ordinary one-way
ANOVA was performed on each data set. A non-linear regression curve fit analysis over the dilution curve
was performed to calculate EC50 and CC50 of the compounds. Cell viability, dose response curve, and
EC50 with 95% confidence intervals are indicated on the graph (Figure S2).
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